Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.67 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.67 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | PPARD | Q03181 | 2/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TYR | P14679 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20746468 | 0.90 | CDK1 (0.66) | CDK1CCNB1CA2CA9LDHA | |
| SCHEMBL6700763 | 0.89 | CDK1 (0.65) | CDK1CCNB1CA2CA9LDHA | |
| SCHEMBL3400018 | 0.88 | CDK1 (0.64) | CDK1CCNB1CA2CA9LDHA | |
| SCHEMBL26185797 | 0.87 | CDK1 (0.69) | CDK1CCNB1CA2CA9LDHA | |
| SCHEMBL17165136 | 0.87 | CDK1 (0.69) | CDK1CCNB1CA2CA9LDHA | |
| SCHEMBL27667174 | 0.86 | CDK1 (0.70) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL3400014 | 0.85 | CDK1 (0.65) | CDK1CCNB1CA2CA9LDHA | |
| SCHEMBL27943621 | 0.84 | CDK1 (0.65) | CDK1CCNB1CA2CA9LDHA | |
| SCHEMBL245645 | 0.84 | CDK1 (0.79) | CDK1CCNB1CA2CA9LDHA | |
| SCHEMBL8994672 | 0.84 | CDK1 (0.67) | CDK1CCNB1CA2CA9LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11987630-B2 | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-21 | — | — | US | disclosed |
| US-20230374593-A1 | PKD MUTATIONS AND EVALUATION OF SAME | ATHENA DIAGNOSTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-11655508-B2 | PKD mutations and evaluation of same | ATHENA DIAGNOSTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11339217-B2 | Methods and agents for the diagnosis and treatment of hepatocellular carcinoma | CIRCULAR COMMITMENT COMPANY (TW) | 2022-05-24 | — | — | US | disclosed |
| US-20210347896-A1 | Anti-Vista Antibodies And Fragments, Uses Thereof, And Methods Of Identifying Same | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-11 | — | — | US | disclosed |
| US-20210318322-A1 | ANTI-VISTA ANTIBODIES AND FRAGMENTS | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-14 | — | — | US | disclosed |
| US-20210171640-A1 | ANTI-VISTA ANTIBODIES AND FRAGMENTS, USES THEREOF, AND METHODS OF IDENTIFYING SAME | JANSSEN PHARMACEUTICA NV | 2021-06-10 | — | — | US | disclosed |
| US-11014987-B2 | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same | JANSSEN PHARMACEUTICS NV (BE) | 2021-05-25 | — | — | US | disclosed |
| US-11009509-B2 | Anti-VISTA antibodies and fragments | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-18 | — | — | US | disclosed |
| US-20210079472-A1 | PKD MUTATIONS AND EVALUATION OF SAME | ATHENA DIAGNOSTICS, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| WO-2001002606-A2 | GENETIC TEST TO DETERMINE NON-RESPONSIVENESS TO STATIN DRUG TREATMENT | CEDARS-SINAI MEDICAL CENTER (US) | 2001-01-11 | — | — | WO | disclosed |
| WO-2000069257-A2 | GENETIC MODIFICATION OF MALE GERM CELLS FOR GENERATION OF TRANSGENIC SPECIES AND GENETIC THERAPIES | CEDARS-SINAI MEDICAL CENTER (US) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000058518-A2 | GENETIC MARKER TEST FOR LUPUS | CEDARS-SINAI MEDICAL CENTER (US) | 2000-10-05 | — | — | WO | disclosed |
| EP-1030929-A1 | TRANSFECTION AND TRANSFER OF MALE GERM CELLS FOR GENERATION OF TRANSGENIC SPECIES | CEDARS-SINAI MEDICAL CENTER (US) | 2000-08-30 | — | — | EP | disclosed |
| WO-1999025863-A1 | TRANSFECTION AND TRANSFER OF MALE GERM CELLS FOR GENERATION OF TRANSGENIC SPECIES | CEDARS-SINAI MEDICAL CENTER (US) | 1999-05-27 | — | — | WO | disclosed |
| US-RE34077-E | Colloid suspension of water, electrolyte, dextran, dextrose, magnesium and potassium compounds | CRYOMEDICAL SCIENCES, INC. (US) | 1992-09-22 | — | — | US | disclosed |
| US-5130230-A | A solution of water, electrolytes, buffers, sugars, oncotic agents, sugars and potassium ion with a cardioplegia maintenance solution | CRYOMEDICAL SCIENCES, INC. (US) | 1992-07-14 | — | — | US | disclosed |
| EP-0414815-A1 | BLOOD SUBSTITUTE | CRYOMEDICAL SCIENCES, INC. (US) | 1991-03-06 | — | — | EP | disclosed |
| US-4923442-A | AQUEOUS ELECTROLYTE-SUGAR SOLUTION FOR LOW TEMPERATURE SURGERY | CRYOMEDICAL SCIENCES INC. (US) | 1990-05-08 | — | — | US | disclosed |
| WO-1989010746-A2 | BLOOD SUBSTITUTE | CRYOMEDICAL SCIENCES INC. (US) | 1989-11-16 | — | — | WO | disclosed |